Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994827 | 0.91 | KCNJ1 (0.33) | ALDH1A1L3MBTL1ADRB3ADRA2BADRA2C | |
| SCHEMBL994824 | 0.91 | KCNJ1 (0.33) | ALDH1A1L3MBTL1ADRB3ADRA2BADRA2C | |
| SCHEMBL8239161 | 0.91 | KCNJ1 (0.33) | ALDH1A1L3MBTL1ADRB3ADRA2BADRA2C | |
| SCHEMBL8249055 | 0.86 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1ADRB3ADRA2BADRA2C | |
| SCHEMBL995274 | 0.86 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1ADRB3ADRA2BADRA2C | |
| SCHEMBL995273 | 0.86 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1ADRB3ADRA2BADRA2C | |
| SCHEMBL995888 | 0.85 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1ADRB3ADRA2BADRA2C | |
| SCHEMBL8239738 | 0.85 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1ADRB3ADRA2BADRA2C | |
| SCHEMBL10156974 | 0.85 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1ADRB3ADRA2BADRA2C | |
| SCHEMBL995885 | 0.85 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1ADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | MEDIVIR AB | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | COPB1, HAVCR2, NOD1 | ALDH1A1 922/4885L3MBTL1 3419/4885ADRB3 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.